Sign In
Buy LOBEF
$0.0540
-0.0110 (-16.91%)
At Close: Jul 31, 2026
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
08:00am, Tuesday, 04'th Apr 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to disco
Lobe Sciences partner gets DEA quota to produce psilocin drug for two studies
11:01am, Wednesday, 22'nd Mar 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) announced that its exclusive commercial manufacturing partner has received an initial 2023 quota for the company's novel psilocin drug product (L-130) from th
Lobe Sciences to advance two new chemical entities through exclusive agreement with Quality Chemical Laboratories
09:32am, Tuesday, 21'st Feb 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said its exclusive discovery and manufacturing partner Quality Chemical Laboratories LLC (QLC) has initiated commercial formulation activities for the company
Lobe Sciences outlines "ambitious but doable" plans for 2023
09:47am, Wednesday, 18'th Jan 2023
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it expects to have two active Investigational New Drug applications in progress with the US Food and Drug Administration (FDA) by the year-end for its ne
Lobe Sciences provides update on clinical development of its proprietary psilocin compound L-130
10:34am, Wednesday, 30'th Nov 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has received regulatory clearance to conduct a Phase 1 study evaluating the safety and pharmacokinetics of a fixed dose of its proprietary psilocin-ba
Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022
09:20am, Tuesday, 08'th Nov 2022
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Executive Director
News snapshot: Love Pharma, Lobe Sciences, Electra Battery Materials, The Valens Company UPDATE
05:03pm, Thursday, 13'th Oct 2022News snapshot: Love Pharma, Lobe Sciences, Electra Battery Materials, The Valens Company
10:59am, Thursday, 13'th Oct 2022Lobe Sciences completes production of psilocin analogues for use in clinical trials
09:29am, Thursday, 13'th Oct 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has completed the synthesis of bulk L-130, a proprietary form of psilocin that has the potential to treat severe forms of anxiety. Lobe CEO Philip J
Lobe Sciences recruits biotech and pharma leader to its board
09:56am, Wednesday, 05'th Oct 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has added more than 20 years of leadership experience to its board with the appointment of Baxter F Phillips III, including as the chair of its audit committ
Lobe Sciences announces expansion of patent portfolio with international filings
07:44am, Tuesday, 04'th Oct 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia. The filin
Lobe Sciences incorporates Australian subsidiary to facilitate clinical trials for psilocin analogues with partner iNGENū
08:59am, Friday, 23'rd Sep 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has incorporated its 100% owned Australian subsidiary Lobe Sciences Australia Pty Ltd to facilitate three or more trials in Australia with its newly a
Lobe Sciences secures $1.3M private placement to fund advancement of its brain trauma-treating psilocin analogs
03:29pm, Thursday, 08'th Sep 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has closed a non-brokered private placement of units for gross proceeds of more than $1.3 million that the company plans to put towards advancing hum
Lobe Sciences inks US$1.5M investment agreement to fund Australian clinical trials
10:26am, Thursday, 01'st Sep 2022
Lobe Sciences Ltd announced that it has entered into a term sheet with Cantheon Capital to raise up US$1.5 million, by means of a convertible note financing that would bear interest at 15% per annum w
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) doesn't just imagine a future where patients can access innovative psychedelics-based treatments for a range of mental and physical conditions from their home
